Panelists discuss how social determinants of health significantly impact AML care, particularly regarding transportation ...
Panelists discuss how current NCCN guidelines emphasize the importance of treating AML at experienced centers with proper ...
PRESS RELEASE AB SCIENCE PROVIDES INITIAL PHASE 1 DATA FOR THE COMBINATION OF AB8939 WITH VENETOCLAX FOR THE TREATMENT OF REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA Paris, 16 October 2025, 9pm CET ...
Results of a recently published long-term follow-up of the ASAP trial, which was conducted at universities and clinics across ...
An international study conducted by the Alliance for Clinical Trials in Oncology and the Acute Myeloid Leukemia Cooperative Group reveals that age-based classifications in the treatment of acute ...
Data from Phase 1/2 TUSCANY trial presented at the European School of Haematology (ESH) 7th International ConferenceAddition ...
Despite improved outcomes in newly diagnosed pediatric AML, relapsed disease remains a therapeutic challenge. Factors contributing to slow progress in improving outcomes include inherent challenges in ...
Medications for AML include chemotherapy and newer targeted therapies. With several options available, the right medication for you will depend on the specific characteristics of your cancer. Acute ...
A Ludwig Cancer Research study has identified a novel strategy for treating acute myelogenous leukemia (AML), an aggressive blood cancer for which the median survival time following diagnosis remains ...
Comparison of CSF Cytology and Spinal Magnetic Resonance Imaging in the Detection of Leptomeningeal Disease in Pediatric Medulloblastoma or Primitive Neuroectodermal Tumor PURPOSE: To identify the ...
Secondary acute myeloid leukemia (AML) is a blood cancer that arises from other blood disorders or previous cancer treatment. Those with secondary AML tend to have a less favorable outlook than those ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback